跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
POTELIGEO
Authorized
STANDARD
POTELIGEO
Kyowa Kirin, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ae740857df21cf54
Company
Kyowa Kirin, Inc.
Type
Standard
Approval Details
Approval Id
ae740857df21cf54
Drug Approval Canada Name
POTELIGEO
Product Name
POTELIGEO
Status
Marketed
Status Date
2024-03-27
Original Market Date
2024-03-27
Din
02527715
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FX09 MOGAMULIZUMAB
Atc Name
l 01 fx 09
Aig Number
0163781001
Company Name
Kyowa Kirin, Inc.
Company Address
510 Carnegie Center, Suite 600, Princeton, New Jersey, United States, 08540
Company Detail Path
/organization/kyowa-kirin-inc
Company Information
Pharmaceutical Company Name
Kyowa Kirin, Inc.
Country Name
Japan
Province Name
New Jersey
City Name
princeton,new jersey,country_us
Address
510 Carnegie Ctr Ste 600
Website
http://www.kyowa-kirin.co.jp/
Active Ingredients
MOGAMULIZUMAB
4 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ae740857df21cf54
Type
Standard
Back to Health Canada Approvals
POTELIGEO - Health Canada Drug Approval Details